Get the Stockscreener App
3.92
4.70%
0.20
Avalo Therapeutics Inc stock is traded at $3.92, with a volume of 41,239.
It is up +4.70% in the last 24 hours and down -21.79% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$3.72
Open:
$3.78
24h Volume:
41,239
Relative Volume:
0.57
Market Cap:
$42.78M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00111
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+3.87%
1M Performance:
-21.79%
6M Performance:
-59.21%
1Y Performance:
-66.85%
1-Day Range:
$3.61
$3.95
1-Week Range:
$3.4313
$3.95
52-Week Range:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
3.95 | 42.34M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.78 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.08 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.14 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics to Participate in Upcoming Investor Conferenc - GuruFocus
Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Tower Research Capital LLC TRC - Defense World
Strong Cash Position Secures AVTX Through 2027 | AVTX Stock News - GuruFocus
Avalo Therapeutics Reports Improved Financial Performance - TipRanks
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics reports Q1 EPS ($1.25) vs. ($141.14) last year - TipRanks
Avalo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
AVTX Advances Phase 2 LOTUS Trial, Targets 2026 Data | AVTX Stoc - GuruFocus
AVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly Earnings - Nasdaq
Avalo Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-Q Report - TradingView
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire Inc.
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Avalo Therapeutics Updates on AVTX-009 and LOTUS Trial - TipRanks
15,323 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Acquired by Marshall Wace LLP - Defense World
When the Price of (AVTX) Talks, People Listen - news.stocktradersdaily.com
Geode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March - Defense World
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
Advanced Cancer Pain Management Therapeutics Market Size in 7MM - openPR.com
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics names new Chairman amid growth phase - Investing.com
DynaCERT And Avalo Therapeutics Poised For Growth - Evrim Ağacı
Stifel initiates Avalo Therapeutics stock with a Buy rating By Investing.com - Investing.com Australia
Jefferies Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
Jefferies starts Avalo stock with Buy, sets $23 price target By Investing.com - Investing.com Australia
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target - MarketScreener
How the (AVTX) price action is used to our Advantage - news.stocktradersdaily.com
Jefferies starts Avalo stock with Buy, sets $23 price target - Investing.com
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):